APT(SH:688617)2023-04-06 16:00Financial Performance - The company's total revenue for 2022 was RMB 828.69 million, representing a 46.74% increase compared to RMB 479.44 million in 2021[23]. - Net profit attributable to shareholders for 2022 was RMB 207.92 million, a 72.19% increase from RMB 110.78 million in 2021[23]. - The net profit after deducting non-recurring gains and losses was RMB 167.58 million, up 92.02% from RMB 97.74 million in 2021[23]. - The net cash flow from operating activities increased by 102.58% to RMB 181.39 million, compared to RMB 148.24 million in 2021[23]. - Basic earnings per share for 2022 were RMB 5.38, a 68.65% increase from RMB 3.19 in 2021[24]. - Operating profit reached CNY 396,988,398.43, up 78.42% compared to the previous year[88]. - Net profit attributable to shareholders was CNY 358,019,712.33, reflecting a growth of 72.19% year-on-year[88]. - The gross margin for the main business was 71.28%, an increase of 1.77 percentage points from the previous year[92]. - The company achieved operating revenue of CNY 1,216,017,969.28, a year-on-year increase of 46.74%[88]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 16.50 per 10 shares, totaling approximately RMB 109.49 million, which represents 47.34% of the net profit attributable to shareholders for the year 2022[5]. - The total amount of dividends (including tax) is CNY 169,481,513.55, representing 47.34% of the net profit attributable to ordinary shareholders in the consolidated financial statements[171]. Research and Development - The company's R&D investment as a percentage of revenue was 14.38%, down from 16.28% in 2021[24]. - R&D investment over the past three years was 71.9 million, 134.9 million, and 174.9 million CNY, representing 15.00%, 16.28%, and 14.38% of revenue respectively[34]. - The company reported a total R&D investment of ¥174,876,346.09 in the current year, representing a 29.66% increase from ¥134,876,802.74 in the previous year[61]. - The company filed 50 new patent applications during the reporting period, with 15 patents granted, bringing the cumulative total to 297 applications and 140 granted[60]. - The company has invested a total of ¥30,888.36 million in R&D projects, with ¥8,477.93 million invested in the current period and a cumulative investment of ¥21,815.48 million[67]. Market Expansion and Strategy - The company plans to continue expanding its market presence and enhancing its product lines, particularly in overseas markets and OEM business[23]. - The company expanded its domestic market presence by adding over 300 new hospitals for electrophysiology products, increasing its coverage to over 800 hospitals[32]. - International business grew by 72.05% year-on-year, with Eastern Europe, CIS, and Western Europe seeing growth exceeding 100%[34]. - The company plans to continue investing in new product and technology development while enhancing market expansion efforts[32]. - The company aims to enhance its product line in electrophysiology and vascular intervention, focusing on innovation and market expansion to maintain a competitive edge[119]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures for providing guarantees[8]. - The company has not experienced any situation where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has not reported any special arrangements for corporate governance[6]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[7]. Risk Management - The company has detailed various risks and countermeasures in the report, which can be found in the "Management Discussion and Analysis" section[3]. - The company is facing significant risks related to new product development failures and registration challenges in the interventional medical device industry, which has high R&D difficulty and barriers[79]. - The company is exposed to macroeconomic risks, including currency fluctuations and depreciation of local currencies, which can impact purchasing power and overall market conditions[86]. Employee and Talent Development - The company emphasizes talent development and has built a high-quality team across various disciplines to support its strategic goals[35]. - The company has established a competitive compensation system to attract and retain talent, including performance bonuses and stock incentives[165]. - The company plans to invest in talent development and management culture to support its rapid growth objectives in 2023[127]. - The company is committed to continuous employee training and career development opportunities, fostering a supportive work environment[199]. Environmental and Social Responsibility - The company invested approximately 2.3 million RMB in environmental protection measures during the reporting period[183]. - The company has implemented measures to reduce carbon emissions, although specific tonnage reductions were not disclosed[189]. - The company donated a total of 2.77 million RMB to various charitable foundations and projects during the reporting period[193]. - The company actively supports rural revitalization through educational assistance and infrastructure development, aligning with national policies[197]. Internal Control and Compliance - The internal control system of the company operated effectively during the reporting period, with no significant control deficiencies identified[179]. - The company received a standard unqualified opinion on its internal control audit for the 2022 financial report, confirming the effectiveness of its internal controls[181]. - The company is committed to strict compliance with laws and regulations to optimize its governance structure and decision-making processes[128].